Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma.
10.3760/cma.j.cn112138-20230202-00049
- Collective Name:Specialist Group of Interventional Drugs, Interventionalists Branch of Chinese Medical Doctor Association
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Consensus;
East Asian People;
Liver Neoplasms/pathology*;
Pharmaceutical Preparations;
Infusions, Intra-Arterial/methods*;
Antineoplastic Agents/therapeutic use*;
Drug Therapy, Combination/methods*
- From:
Chinese Journal of Internal Medicine
2023;62(7):785-801
- CountryChina
- Language:Chinese
-
Abstract:
Transarterial interventional therapy is one of the most widely used treatment methods in patients with primary hepatocellular carcinoma. With the progress in interventional technology and the use of new drugs, transarterial interventional therapy has achieved favorable results in the treatment of primary hepatocellular carcinoma and has become the first choice non-surgical treatment for advanced liver cancer. However, at present, there are great differences in the drugs used in transarterial interventional treatment and the combined application of other drugs among centers, and there is no uniform consensus or guideline. Based on the latest research data and clinical practice experience, as well as the characteristics of Chinese patients, the Specialist Group of Interventional Drugs, Interventionalists Branch of the Chinese Medical Doctor Association was organized to formulate the Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma. The purpose of this consensus is to explore the efficacy and safety of drugs and drug combinations related to intra-arterial interventional therapy, the use of drugs in special populations, the management of adverse reactions, and adjuvant drugs to provide a reference for clinical practice.
